Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 20/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728802 | 0.85 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2730687 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL771716 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2719265 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2728400 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2731776 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL8307735 | 0.82 | CYP11B1 (0.97) | CYP11B1CYP11B2CYP19A1 | |
| Hydrazine SCHEMBL28019549 | 0.81 | CYP11B1 (0.94) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2728383 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2729398 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394290-B2 | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases | UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | UNIVERSITAET DES SAARLANDES (DE) | 2014-06-05 | — | — | US | disclosed |
| EP-2630136-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012052540-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | UNIVERSITAET DES SAARLANDES (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | HSD11B1, CYP11B1, HSD11B2 | CYP11B1 2/4885CYP11B2 4/4885CYP19A1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.